SG10202002612PA - Novel immunotherapy against several tumors, such as lung cancer, including nsclc - Google Patents

Novel immunotherapy against several tumors, such as lung cancer, including nsclc

Info

Publication number: SG10202002612PA
Authority: SG; Singapore
Prior art keywords: lung cancer; against several; immunotherapy against; several tumors; including nsclc
Prior art date: 2013-08-05

Application number

SG10202002612PA

Inventor

Toni Weinschenk

Steffen Walter

Jens Fritsche

Colette Song

Harpreet Singh

Original Assignee

Immatics Biotechnologies Gmbh

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2013-08-05

Filing date

2014-08-04

Publication date

2020-05-28

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=52460698&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SG10202002612P(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2013-08-05 Priority claimed from GBGB1313987.8A external-priority patent/GB201313987D0/en

2014-02-25 Priority claimed from GBGB1403297.3A external-priority patent/GB201403297D0/en

2014-08-04 Application filed by Immatics Biotechnologies Gmbh filed Critical Immatics Biotechnologies Gmbh

2020-05-28 Publication of SG10202002612PA publication Critical patent/SG10202002612PA/en

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/10—Peptides having 12 to 20 amino acids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
- C12N5/0638—Cytotoxic T lymphocytes [CTL] or lymphokine activated killer cells [LAK]
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
- C12N9/6489—Metalloendopeptidases (3.4.24)
- C12N9/6491—Matrix metalloproteases [MMP's], e.g. interstitial collagenase (3.4.24.7); Stromelysins (3.4.24.17; 3.2.1.22); Matrilysin (3.4.24.23)
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/24—Metalloendopeptidases (3.4.24)
- C12Y304/24065—Macrophage elastase (3.4.24.65), i.e. metalloelastase
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2502/00—Coculture with; Conditioned medium produced by
- C12N2502/11—Coculture with; Conditioned medium produced by blood or immune system cells

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Engineering & Computer Science (AREA)
Organic Chemistry (AREA)
Immunology (AREA)
General Health & Medical Sciences (AREA)
Genetics & Genomics (AREA)
Medicinal Chemistry (AREA)
Zoology (AREA)
Bioinformatics & Cheminformatics (AREA)
Biomedical Technology (AREA)
Wood Science & Technology (AREA)
Biochemistry (AREA)
Biotechnology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Epidemiology (AREA)
Cell Biology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Molecular Biology (AREA)
General Engineering & Computer Science (AREA)
Microbiology (AREA)
Biophysics (AREA)
Hematology (AREA)
Gastroenterology & Hepatology (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Oncology (AREA)
Mycology (AREA)
Virology (AREA)
Developmental Biology & Embryology (AREA)
Marine Sciences & Fisheries (AREA)
Toxicology (AREA)
Physics & Mathematics (AREA)
Plant Pathology (AREA)
Peptides Or Proteins (AREA)

SG10202002612PA 2013-08-05 2014-08-04 Novel immunotherapy against several tumors, such as lung cancer, including nsclc SG10202002612PA (en)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US201361862213P	2013-08-05	2013-08-05
GBGB1313987.8A GB201313987D0 (en)	2013-08-05	2013-08-05	Novel immunotherapy against several tumors, such as lung cancer including NSCLC
GBGB1403297.3A GB201403297D0 (en)	2014-02-25	2014-02-25	Novel immunotherapy against several tumors, such as lung cancer, including NSCLC

Publications (1)

Publication Number	Publication Date
SG10202002612PA true SG10202002612PA (en)	2020-05-28

Family

ID=52460698

Family Applications (4)

Application Number	Title	Priority Date	Filing Date
SG10202002612PA SG10202002612PA (en)	2013-08-05	2014-08-04	Novel immunotherapy against several tumors, such as lung cancer, including nsclc
SG11201510580UA SG11201510580UA (en)	2013-08-05	2014-08-04	Novel immunotherapy against several tumors, such as lung cancer, including nsclc
SG10201802399WA SG10201802399WA (en)	2013-08-05	2014-08-04	Novel immunotherapy against several tumors, such as lung cancer, including nsclc
SG10202002608WA SG10202002608WA (en)	2013-08-05	2014-08-04	Novel immunotherapy against several tumors, such as lung cancer, including nsclc

Family Applications After (3)

Application Number	Title	Priority Date	Filing Date
SG11201510580UA SG11201510580UA (en)	2013-08-05	2014-08-04	Novel immunotherapy against several tumors, such as lung cancer, including nsclc
SG10201802399WA SG10201802399WA (en)	2013-08-05	2014-08-04	Novel immunotherapy against several tumors, such as lung cancer, including nsclc
SG10202002608WA SG10202002608WA (en)	2013-08-05	2014-08-04	Novel immunotherapy against several tumors, such as lung cancer, including nsclc

Country Status (28)

Country	Link
US (3)	US20160168200A1 (en)
EP (10)	EP3456339B1 (en)
JP (1)	JP2016527293A (en)
KR (9)	KR102217680B1 (en)
CN (1)	CN105377290B (en)
AU (10)	AU2014304544B2 (en)
BR (1)	BR112016000810A2 (en)
CA (4)	CA3020939C (en)
CL (1)	CL2016000227A1 (en)
CR (4)	CR20210464A (en)
DK (2)	DK3456339T3 (en)
EA (1)	EA035362B1 (en)
ES (1)	ES2764406T3 (en)
HU (1)	HUE047079T2 (en)
IL (1)	IL243788B (en)
LT (1)	LT3030255T (en)
MX (1)	MX389568B (en)
NZ (2)	NZ714163A (en)
PE (3)	PE20160717A1 (en)
PH (1)	PH12015502638A1 (en)
PL (1)	PL3030255T3 (en)
PT (1)	PT3030255T (en)
RS (1)	RS59861B1 (en)
SG (4)	SG10202002612PA (en)
SI (1)	SI3030255T1 (en)
TW (10)	TWI636065B (en)
UA (1)	UA122661C2 (en)
WO (1)	WO2015018805A1 (en)

Families Citing this family (75)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US10704021B2 (en)	2012-03-15	2020-07-07	Flodesign Sonics, Inc.	Acoustic perfusion devices
SI3456339T1 (en) *	2013-08-05	2022-01-31	Immatics Biotechnologies Gmbh	New immunotherapy against several tumors, such as lung cancer, including non-small cell lung cancer
US9725710B2 (en)	2014-01-08	2017-08-08	Flodesign Sonics, Inc.	Acoustophoresis device with dual acoustophoretic chamber
GB201504502D0 (en) *	2015-03-17	2015-04-29	Immatics Biotechnologies Gmbh	Novel peptides and combination of peptides for use in immunotherapy against pancreatic cancer and other cancers
TWI755158B (en)	2015-03-17	2022-02-11	德商英麥提克生物技術股份有限公司	Novel peptides and combination of peptides for use in immunotherapy against pancreatic cancer and other cancers
RS64397B1 (en)	2015-03-27	2023-08-31	Immatics Biotechnologies Gmbh	Novel peptides and combination of peptides for use in immunotherapy against various tumors (seq id 25 - mrax5-003)
GB201505305D0 (en)	2015-03-27	2015-05-13	Immatics Biotechnologies Gmbh	Novel Peptides and combination of peptides for use in immunotherapy against various tumors
GB201505585D0 (en)	2015-03-31	2015-05-13	Immatics Biotechnologies Gmbh	Novel peptides and combination of peptides and scaffolds for use in immunotherapy against renal cell carinoma (RCC) and other cancers
TWI772927B (en) *	2015-03-31	2022-08-01	德商英麥提克生物技術股份有限公司	Novel peptides and combination of peptides and scaffolds for use in immunotherapy against renal cell carcinoma (rcc) and other cancers
GB201507030D0 (en)	2015-04-24	2015-06-10	Immatics Biotechnologies Gmbh	Immunotherapy against lung cancers, in particular NSCLC
US11377651B2 (en)	2016-10-19	2022-07-05	Flodesign Sonics, Inc.	Cell therapy processes utilizing acoustophoresis
US11708572B2 (en)	2015-04-29	2023-07-25	Flodesign Sonics, Inc.	Acoustic cell separation techniques and processes
KR20240161207A (en) *	2015-05-06	2024-11-12	이매틱스 바이오테크놀로지스 게엠베하	Novel peptides and combination of peptides and scaffolds thereof for use in immunotherapy against colorectal carcinoma (crc) and other cancers
GB201507719D0 (en)	2015-05-06	2015-06-17	Immatics Biotechnologies Gmbh	Novel peptides and combination of peptides and scaffolds thereof for use in immunotherapy against colorectal carcinoma (CRC) and other cancers
WO2016187508A2 (en) *	2015-05-20	2016-11-24	The Broad Institute Inc.	Shared neoantigens
TWI747524B (en) *	2015-06-19	2021-11-21	德商英麥提克生物技術股份有限公司	Novel peptides and combination of peptides for use in immunotherapy and methods for generating scaffolds for the use against pancreatic cancer and other cancers
EP3919507A3 (en) *	2015-07-01	2022-01-12	Immatics Biotechnologies GmbH	Novel peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers
GB201511546D0 (en)	2015-07-01	2015-08-12	Immatics Biotechnologies Gmbh	Novel peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers
PT3319985T (en)	2015-07-06	2021-01-06	Immatics Biotechnologies Gmbh	Novel peptides and combination of peptides for use in immunotherapy against esophageal cancer and other cancers
GB201512369D0 (en) *	2015-07-15	2015-08-19	Immatics Biotechnologies Gmbh	Novel peptides and combination of peptides for use in immunotherapy against epithelial ovarian cancer and other cancers
GB201513921D0 (en)	2015-08-05	2015-09-23	Immatics Biotechnologies Gmbh	Novel peptides and combination of peptides for use in immunotherapy against prostate cancer and other cancers
GB201515321D0 (en)	2015-08-28	2015-10-14	Immatics Biotechnologies Gmbh	Novel peptides, combination of peptides and scaffolds for use in immunotherapeutic treatment of various cancers
IL292864A (en) *	2015-08-28	2022-07-01	Immatics Biotechnologies Gmbh	New peptides and a combination of peptides and supports for use in immunotherapy in certain types of cancer
US10130693B2 (en)	2015-08-28	2018-11-20	Immatics Biotechnologies Gmbh	Peptides, combination of peptides and scaffolds for use in immunotherapeutic treatment of various cancers
GB201517538D0 (en) *	2015-10-05	2015-11-18	Immatics Biotechnologies Gmbh	Novel peptides and combination of peptides for use in immunotherapy against small cell lung cancer and other cancers
PH12022551111A1 (en)	2015-10-05	2023-08-23	Immatics Biotechnologies Gmbh	Peptides and combination of peptides for use in immunotherapy against small cell lung cancer and other cancers
KR20170049024A (en) *	2015-10-28	2017-05-10	숙명여자대학교산학협력단	Composition for prevention or treating cancer comprising inhibitors for expression or activity of ANKs1a, and screening method for thereof
GB201521746D0 (en)	2015-12-10	2016-01-27	Immatics Biotechnologies Gmbh	Novel peptides and combination of peptides for use in immunotherapy against CLL and other cancers
GB201521894D0 (en)	2015-12-11	2016-01-27	Immatics Biotechnologies Gmbh	Novel peptides and combination of peptides for use in immunotherapy against various cancers
HK1255541A1 (en)	2015-12-11	2019-08-23	Immatics Biotechnologies Gmbh	Novel peptides and combination of peptides for use in immunotherapy against various cancers
US10383896B2 (en)	2015-12-11	2019-08-20	Immatics Biotechnologies Gmbh	Peptides and combination of peptides for use in immunotherapy against various cancers
CA3008641A1 (en)	2015-12-16	2017-06-22	Gritstone Oncology, Inc.	Neoantigen identification, manufacture, and use
GB201522667D0 (en) *	2015-12-22	2016-02-03	Immatics Biotechnologies Gmbh	Novel peptides and combination of peptides for use in immunotherapy against breast cancer and other cancers
HRP20210698T1 (en) *	2015-12-22	2021-09-17	Immatics Biotechnologies Gmbh	Peptides and combination of peptides for use in immunotherapy against breast cancer and other cancers
GB201602918D0 (en) *	2016-02-19	2016-04-06	Immatics Biotechnologies Gmbh	Novel peptides and combination of peptides for use in immunotherapy against NHL and other cancers
GB201603987D0 (en) *	2016-03-08	2016-04-20	Immatics Biotechnologies Gmbh	Uterine cancer treatments
GB201604458D0 (en)	2016-03-16	2016-04-27	Immatics Biotechnologies Gmbh	Peptides and combination of peptides for use in immunotherapy against cancers
CN109071605A (en) *	2016-04-06	2018-12-21	伊玛提克斯生物技术有限公司	New type of peptides and peptide combinations for AML and other cancer immunotherapies
PE20181897A1 (en) *	2016-04-21	2018-12-11	Immatics Biotechnologies Gmbh	IMMUNOTHERAPY AGAINST MELANOMA AND OTHER TYPES OF CANCER
US11214789B2 (en)	2016-05-03	2022-01-04	Flodesign Sonics, Inc.	Concentration and washing of particles with acoustics
GB201609193D0 (en)	2016-05-25	2016-07-06	Immatics Biotechnologies Gmbh	Novel peptides, combination of peptides as targets for use in immunotherapy against gallbladder cancer and cholangiocarcinoma and other cancers
JP7075125B2 (en)	2016-05-25	2022-05-25	イマティクスバイオテクノロジーズゲーエムベーハー	A novel peptide, peptide combination as a target and for use in immunotherapy for gallbladder cancer and cholangiocarcinoma and other cancers
US10868749B2 (en) *	2016-07-26	2020-12-15	Motorola Mobility Llc	Method and apparatus for discovering neighborhood awareness networking devices based on presence
MD3500593T2 (en) *	2016-08-17	2021-12-31	Immatics Biotechnologies Gmbh	T cell receptors and immune therapy using the same
TW202304970A (en)	2016-08-26	2023-02-01	德商英麥提克生物技術股份有限公司	Novel peptides and scaffolds for use in immunotherapy against head and neck squamous cell carcinoma and other cancers
EP3516081A4 (en) *	2016-09-23	2020-07-29	Memorial Sloan Kettering Cancer Center	DETERMINANTS OF CANCER REACTION TO IMMUNOTHERAPY
WO2018058490A1 (en) *	2016-09-30	2018-04-05	武汉华大吉诺因生物科技有限公司	Col14a1-derived tumour antigen polypeptide and use thereof
EP3548897A4 (en) *	2016-12-01	2020-08-12	Nantomics, LLC	Tumor antigenicity processing and presentation
KR102379955B1 (en)	2016-12-08	2022-03-29	이매틱스 바이오테크놀로지스 게엠베하	Mating Enhanced T Cell Receptor
DE102016123893A1 (en)	2016-12-08	2018-06-14	Immatics Biotechnologies Gmbh	T cell receptors with improved binding
WO2018170313A1 (en) *	2017-03-16	2018-09-20	Advaxis, Inc.	Methods and compositions for increasing efficacy of vaccines
CN110944660A (en) *	2017-04-10	2020-03-31	伊玛提克斯生物技术有限公司	Peptides and peptide compositions for immunotherapy of leukemia and other cancers
JP7357292B2 (en) *	2017-04-28	2023-10-06	チュンシャンメディカルユニバーシティ	Peptides for cancer treatment
JP2020518648A (en)	2017-05-08	2020-06-25	グリットストーンオンコロジーインコーポレイテッド	Alphavirus neonatal antigen vector
US10800823B2 (en)	2017-07-07	2020-10-13	Immatics Biotechnologies Gmbh	Peptides and combination of peptides for use in immunotherapy against lung cancer, including NSCLC, SCLC and other cancers
KR20250007011A (en)	2017-07-07	2025-01-13	이매틱스 바이오테크놀로지스 게엠베하	Novel peptides and combination of peptides for use in immunotherapy against lung cancer, including nsclc, sclc and other cancers
WO2019075112A1 (en)	2017-10-10	2019-04-18	Gritstone Oncology, Inc.	Neoantigen identification using hotspots
GB201717578D0 (en) *	2017-10-26	2017-12-13	Univ College Cardiff Consultants Ltd	Novel T-cell receptor
EP3714275A4 (en)	2017-11-22	2021-10-27	Gritstone bio, Inc.	REDUCTION OF CONNECTING EPITOPES FOR NEOANTIGENS
US10785574B2 (en)	2017-12-14	2020-09-22	Flodesign Sonics, Inc.	Acoustic transducer driver and controller
DE102018107224A1 (en)	2018-02-21	2019-08-22	Immatics Biotechnologies Gmbh	Peptides and combinations of peptides of non-canonical origin for use in immunotherapy against various cancers
TW202016131A (en) *	2018-05-16	2020-05-01	德商英麥提克生物技術股份有限公司	Peptides for use in immunotherapy against cancers
AU2019275072A1 (en) *	2018-05-23	2021-01-21	Seattle Project Corp.	Shared antigens
CN110627895B (en) *	2018-06-25	2021-03-23	北京大学	Lung cancer specific TCR and analysis technology and application thereof
US10925947B2 (en) *	2018-06-29	2021-02-23	Immatics Biotechnologies Gmbh	A*03 restricted peptides for use in immunotherapy against cancers and related methods
EP3946440A4 (en) *	2019-04-02	2023-04-19	The General Hospital Corporation	METHODS FOR ENHANCING T LYMPHOCYTE REGENERATION
AU2020282369A1 (en)	2019-05-30	2022-01-20	Seattle Project Corp.	Modified adenoviruses
WO2021016109A1 (en) *	2019-07-19	2021-01-28	The Regents Of The University Of California	T-cell receptors and methods of use thereof
CN111020024A (en) *	2019-12-05	2020-04-17	复旦大学附属眼耳鼻喉科医院	Application of TLR9
CN111808908A (en) *	2020-06-18	2020-10-23	华中科技大学同济医学院附属协和医院	A method for the detection of gaMSCs subsets that promote glioma drug resistance
WO2022125504A1 (en) *	2020-12-07	2022-06-16	Iogenetics, Llc	Bystander protein vaccines
JP2023552440A (en) *	2020-12-07	2023-12-15	ザ・トラスティーズ・オブ・インディアナ・ユニバーシティー	Methods of Sensitizing Cancer Cells to Immune Attack Using Atractylenolide I
CN113881707B (en) *	2021-10-25	2023-07-14	中国人民解放军军事科学院军事医学研究院	Products, methods and uses for regulating the immunosuppressive effect of umbilical cord mesenchymal stem cells
CN113969264B (en) *	2021-11-29	2023-12-08	中南大学	COG5 gene knockout human embryonic stem cell line, construction method and application
CN115125203B (en) *	2022-07-08	2023-10-27	珠海贝索细胞科学技术有限公司	Th2 cell in-vitro culture method

Family Cites Families (62)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US8212000B2 (en) *	1970-02-11	2012-07-03	Immatics Biotechnologies Gmbh	Tumor-associated peptides binding promiscuously to human leukocyte antigen (HLA) class II molecules
US4440859A (en)	1977-05-27	1984-04-03	The Regents Of The University Of California	Method for producing recombinant bacterial plasmids containing the coding sequences of higher organisms
US4704362A (en)	1977-11-08	1987-11-03	Genentech, Inc.	Recombinant cloning vehicle microbial polypeptide expression
NZ192465A (en)	1978-12-22	1983-09-30	Biogen Nv	Recombinant dna molecule comprising gene coding for polypeptide displaying hbv (hepatitis b virus) antigenicity usesthereof
US4530901A (en)	1980-01-08	1985-07-23	Biogen N.V.	Recombinant DNA molecules and their use in producing human interferon-like polypeptides
US4342566A (en)	1980-02-22	1982-08-03	Scripps Clinic & Research Foundation	Solid phase anti-C3 assay for detection of immune complexes
US4678751A (en)	1981-09-25	1987-07-07	Genentech, Inc.	Hybrid human leukocyte interferons
US4766075A (en)	1982-07-14	1988-08-23	Genentech, Inc.	Human tissue plasminogen activator
US4582800A (en)	1982-07-12	1986-04-15	Hoffmann-La Roche Inc.	Novel vectors and method for controlling interferon expression
US4816567A (en)	1983-04-08	1989-03-28	Genentech, Inc.	Recombinant immunoglobin preparations
US4757006A (en)	1983-10-28	1988-07-12	Genetics Institute, Inc.	Human factor VIII:C gene and recombinant methods for production
US4677063A (en)	1985-05-02	1987-06-30	Cetus Corporation	Human tumor necrosis factor
US4810648A (en)	1986-01-08	1989-03-07	Rhone Poulenc Agrochimie	Haloarylnitrile degrading gene, its use, and cells containing the gene
US4897445A (en)	1986-06-27	1990-01-30	The Administrators Of The Tulane Educational Fund	Method for synthesizing a peptide containing a non-peptide bond
CA2163032C (en)	1993-06-03	2001-02-06	John Landon	Antibody fragments in therapy
AUPM322393A0 (en)	1993-12-24	1994-01-27	Austin Research Institute, The	Mucin carbohydrate compounds and their use in immunotherapy
ATE244300T1 (en)	1996-01-17	2003-07-15	Imp College Innovations Ltd	IMMUNOTHERAPY USING CYTOTOXIC T LYMPHOCYTES (CTL)
US5849589A (en)	1996-03-11	1998-12-15	Duke University	Culturing monocytes with IL-4, TNF-α and GM-CSF TO induce differentiation to dendric cells
US6406705B1 (en)	1997-03-10	2002-06-18	University Of Iowa Research Foundation	Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant
US20040191260A1 (en)	2003-03-26	2004-09-30	Technion Research & Development Foundation Ltd.	Compositions capable of specifically binding particular human antigen presenting molecule/pathogen-derived antigen complexes and uses thereof
EP2316950A1 (en)	2000-03-27	2011-05-04	Technion Research and Development Foundation, Ltd.	Single chain class I major histo-compatibility complexes, constructs encoding same and methods of generating same
AU2001275246B2 (en)	2000-06-05	2006-06-29	Altor Bioscience Corporation	T cell receptor fusions and conjugates and methods of use thereof
US7919467B2 (en) *	2000-12-04	2011-04-05	Immunotope, Inc.	Cytotoxic T-lymphocyte-inducing immunogens for prevention, treatment, and diagnosis of cancer
ATE403149T1 (en) *	2001-08-13	2008-08-15	Dana Farber Cancer Inst Inc	PERIOSTIN-BASED DIAGNOSTIC TESTS
US6992176B2 (en)	2002-02-13	2006-01-31	Technion Research & Development Foundation Ltd.	Antibody having a T-cell receptor-like specificity, yet higher affinity, and the use of same in the detection and treatment of cancer, viral infection and autoimmune disease
CA2476625A1 (en)	2002-02-20	2003-08-28	Dyax Corp.	Mhc-peptide complex binding ligands
WO2004018633A2 (en) *	2002-08-20	2004-03-04	The Government Of The United States Of America As Represented By The Secretary, Department Of Healthand Human Services	Abca13 nucleic acids and proteins, and uses thereof
EP1549748B1 (en)	2002-10-09	2014-10-01	Immunocore Ltd.	Single chain recombinant t cell receptors
ES2327229T3 (en)	2002-11-09	2009-10-27	Immunocore Ltd.	PRESENTATION OF THE RECEIVER OF LYMPHOCYTES T.
GB0304068D0 (en)	2003-02-22	2003-03-26	Avidex Ltd	Substances
KR100535326B1 (en) *	2004-01-20	2005-12-09	한국생명공학연구원	Differentiation regulating agent containing gene which regulating differentiation from stem cell to natural killer cell as effective ingradient
CN102875681A (en) *	2005-07-08	2013-01-16	拜奥根Idec马萨诸塞公司	Anti-alpha v beta 6 antibodies and uses thereof
ES2330013T3 (en) *	2005-09-05	2009-12-03	Immatics Biotechnologies Gmbh	PEPTIDES ASSOCIATED WITH TUMORS UNITED TO MOLECULES OF THE HUMAN LEUCOCITE ANTIGEN (HLA) CLASS I OR II AND RELATED CANCER VACCINES.
ATE461215T1 (en)	2005-09-05	2010-04-15	Immatics Biotechnologies Gmbh	TUMOR-ASSOCIATED PEPTIDES THAT BIND TO DIFFERENT CLASS II HUMAN LEUCOCYTE ANTIGENS
EA200801865A1 (en) *	2006-02-22	2009-02-27	Филоджен Спа	TUMOR MARKERS OF VESSELS
US20080107668A1 (en) *	2006-08-30	2008-05-08	Immunotope, Inc.	Cytotoxic t-lymphocyte-inducing immunogens for prevention, treatment, and diagnosis of cancer
JP5352586B2 (en) *	2007-07-27	2013-11-27	イマティクスバイオテクノロジーズゲーエムベーハー	Composition of tumor-related peptides and related anti-cancer vaccines
WO2009036246A2 (en) *	2007-09-14	2009-03-19	Immunotope, Inc.	Immunogens that induce cytotoxic t-lymphocytes and their use in prevention, treatment, and diagnosis of cancer
US8263743B2 (en) *	2007-11-13	2012-09-11	Teva Biopharmaceuticals Usa, Inc.	Humanized antibodies against TL1A
US7996174B2 (en) *	2007-12-18	2011-08-09	Teradyne, Inc.	Disk drive testing
US8114968B2 (en) *	2008-03-03	2012-02-14	Dyax Corp.	Metalloproteinase-12 specific monoclonal antibody
AU2009234444A1 (en) *	2008-04-11	2009-10-15	China Synthetic Rubber Corporation	Methods, agents and kits for the detection of cancer
PL2113253T3 (en)	2008-04-30	2010-09-30	Immatics Biotechnologies Gmbh	Novel formulations of tumour-associated peptides binding to human leukocyte antigen (HLA) class I or II molecules for vaccines
TWI526219B (en) *	2008-06-19	2016-03-21	腫瘤療法科學股份有限公司	Cdca1 epitope peptides and vaccines containing the same
EP2331577B1 (en) *	2008-08-29	2017-06-07	Symphogen A/S	Recombinant anti-epidermal growth factor receptor antibody compositions
PL2172211T3 (en) *	2008-10-01	2015-05-29	Immatics Biotechnologies Gmbh	A composition of tumor associated peptides and associated cancer vaccine for the treatment of glioblastoma (GBM) and other types of cancer
WO2010045388A2 (en) *	2008-10-14	2010-04-22	Dyax Corp.	Use of mmp-9 and mmp-12 binding proteins for the treatment and prevention of systemic sclerosis
EP2221063A1 (en) *	2009-02-20	2010-08-25	Ganymed Pharmaceuticals AG	Methods and compositions for diagnosis and treatment of cancer
EP2430193B1 (en)	2009-05-15	2016-03-09	Pacific Edge Limited	Markers for detection of gastric cancer
US20110033516A1 (en) *	2009-08-06	2011-02-10	Medical University Of South Carolina	Methods and compositions for bone healing by periostin
US8276032B2 (en)	2009-08-07	2012-09-25	Via Technologies, Inc.	Detection of uncorrectable re-grown fuses in a microprocessor
US20120270769A1 (en) *	2009-10-23	2012-10-25	Marsault Eric	Methods of using macrocyclic inhibitors of serine protease enzymes
TWI485245B (en) *	2010-01-25	2015-05-21	Oncotherapy Science Inc	Modified MELK peptide and vaccine containing the same
KR101378919B1 (en)	2010-01-28	2014-04-14	포항공과대학교 산학협력단	System biological method of biomarker selection for diagnosis of lung cancer, subtype of lung cancer, and biomarker selected by the same
GB201004551D0 (en) *	2010-03-19	2010-05-05	Immatics Biotechnologies Gmbh	NOvel immunotherapy against several tumors including gastrointestinal and gastric cancer
GB201004575D0 (en) *	2010-03-19	2010-05-05	Immatics Biotechnologies Gmbh	Composition of tumor associated peptides and related anti cancer vaccine for the treatment of gastric cancer and other cancers
GB201006360D0 (en)	2010-04-16	2010-06-02	Immatics Biotechnologies Gmbh	Method for differentially quantifying naturally processed HLA-restricted peptides for cancer, autoimmune and infectious diseases immunotherapy development
GB201009222D0 (en) *	2010-06-02	2010-07-21	Immatics Biotechnologies Gmbh	Improved cancer therapy based on tumour associated antigens derived from cyclin D1
CA2816225A1 (en)	2010-10-26	2012-05-03	Technion Research & Development Foundation Ltd.	Antibodies which bind soluble t-cell receptor ligands
US9028810B2 (en) *	2010-12-20	2015-05-12	Ajou University Industry—Academic Cooperations Foundatin	Composition for inducing migration of neural stem cells containing periostin as effective ingredient
WO2013057586A1 (en)	2011-10-19	2013-04-25	Oslo Universitetssykehus Hf	Compositions and methods for producing soluble t - cell receptors
GB201319446D0 (en) *	2013-11-04	2013-12-18	Immatics Biotechnologies Gmbh	Personalized immunotherapy against several neuronal and brain tumors

2014
- 2014-08-01 TW TW103126327A patent/TWI636065B/en not_active IP Right Cessation
- 2014-08-01 TW TW109124803A patent/TWI819228B/en not_active IP Right Cessation
- 2014-08-01 TW TW109124795A patent/TWI777194B/en not_active IP Right Cessation
- 2014-08-01 TW TW109124798A patent/TWI776192B/en not_active IP Right Cessation
- 2014-08-01 TW TW109124799A patent/TWI777196B/en not_active IP Right Cessation
- 2014-08-01 TW TW109124797A patent/TWI777195B/en not_active IP Right Cessation
- 2014-08-01 TW TW109124801A patent/TWI777197B/en not_active IP Right Cessation
- 2014-08-01 TW TW109124796A patent/TWI775117B/en not_active IP Right Cessation
- 2014-08-01 TW TW107123070A patent/TWI714869B/en not_active IP Right Cessation
- 2014-08-01 TW TW109124802A patent/TWI777198B/en not_active IP Right Cessation
- 2014-08-04 UA UAA201600268A patent/UA122661C2/en unknown
- 2014-08-04 EP EP18201334.2A patent/EP3456339B1/en active Active
- 2014-08-04 WO PCT/EP2014/066755 patent/WO2015018805A1/en not_active Ceased
- 2014-08-04 DK DK18201334.2T patent/DK3456339T3/en active
- 2014-08-04 RS RS20191676A patent/RS59861B1/en unknown
- 2014-08-04 EP EP19202056.8A patent/EP3616711B1/en active Active
- 2014-08-04 SG SG10202002612PA patent/SG10202002612PA/en unknown
- 2014-08-04 SG SG11201510580UA patent/SG11201510580UA/en unknown
- 2014-08-04 EP EP19202037.8A patent/EP3616709B1/en active Active
- 2014-08-04 PE PE2015002616A patent/PE20160717A1/en active Application Revival
- 2014-08-04 NZ NZ714163A patent/NZ714163A/en not_active IP Right Cessation
- 2014-08-04 ES ES14750175T patent/ES2764406T3/en active Active
- 2014-08-04 SG SG10201802399WA patent/SG10201802399WA/en unknown
- 2014-08-04 KR KR1020187026992A patent/KR102217680B1/en not_active Expired - Fee Related
- 2014-08-04 KR KR1020167000976A patent/KR102098329B1/en active Active
- 2014-08-04 KR KR1020207018007A patent/KR102211542B1/en not_active Expired - Fee Related
- 2014-08-04 CR CR20210464A patent/CR20210464A/en unknown
- 2014-08-04 HU HUE14750175A patent/HUE047079T2/en unknown
- 2014-08-04 SI SI201431453T patent/SI3030255T1/en unknown
- 2014-08-04 PL PL14750175T patent/PL3030255T3/en unknown
- 2014-08-04 CR CR20180508A patent/CR20180508A/en unknown
- 2014-08-04 US US14/908,078 patent/US20160168200A1/en not_active Abandoned
- 2014-08-04 CA CA3020939A patent/CA3020939C/en active Active
- 2014-08-04 EP EP19202010.5A patent/EP3616707A1/en active Pending
- 2014-08-04 CA CA3073256A patent/CA3073256A1/en active Pending
- 2014-08-04 AU AU2014304544A patent/AU2014304544B2/en not_active Ceased
- 2014-08-04 EP EP19202028.7A patent/EP3616708B1/en active Active
- 2014-08-04 EP EP19202046.9A patent/EP3616710B1/en active Active
- 2014-08-04 PT PT147501753T patent/PT3030255T/en unknown
- 2014-08-04 CA CA2912500A patent/CA2912500C/en active Active
- 2014-08-04 MX MX2016001426A patent/MX389568B/en unknown
- 2014-08-04 KR KR1020207029965A patent/KR102213556B1/en not_active Expired - Fee Related
- 2014-08-04 KR KR1020187026995A patent/KR102098327B1/en active Active
- 2014-08-04 BR BR112016000810A patent/BR112016000810A2/en not_active IP Right Cessation
- 2014-08-04 EA EA201690016A patent/EA035362B1/en unknown
- 2014-08-04 PE PE2018001559A patent/PE20181538A1/en unknown
- 2014-08-04 KR KR1020207029977A patent/KR102213552B1/en not_active Expired - Fee Related
- 2014-08-04 EP EP19202000.6A patent/EP3613427B1/en active Active
- 2014-08-04 KR KR1020207029963A patent/KR102213554B1/en not_active Expired - Fee Related
- 2014-08-04 LT LTEP14750175.3T patent/LT3030255T/en unknown
- 2014-08-04 PE PE2020000409A patent/PE20201284A1/en unknown
- 2014-08-04 DK DK14750175.3T patent/DK3030255T3/en active
- 2014-08-04 EP EP14750175.3A patent/EP3030255B1/en active Active
- 2014-08-04 EP EP19171543.2A patent/EP3578196A1/en active Pending
- 2014-08-04 EP EP19202064.2A patent/EP3616712A1/en not_active Withdrawn
- 2014-08-04 CA CA3073394A patent/CA3073394A1/en active Pending
- 2014-08-04 JP JP2016532350A patent/JP2016527293A/en active Pending
- 2014-08-04 KR KR1020207029978A patent/KR102213551B1/en not_active Expired - Fee Related
- 2014-08-04 SG SG10202002608WA patent/SG10202002608WA/en unknown
- 2014-08-04 KR KR1020217001136A patent/KR102317816B1/en active Active
- 2014-08-04 NZ NZ733168A patent/NZ733168A/en not_active IP Right Cessation
- 2014-08-04 CR CR20200139A patent/CR20200139A/en unknown
- 2014-08-04 CN CN201480035925.8A patent/CN105377290B/en not_active Expired - Fee Related
2015
- 2015-11-26 PH PH12015502638A patent/PH12015502638A1/en unknown
2016
- 2016-01-08 CR CR20160018A patent/CR20160018A/en unknown
- 2016-01-26 IL IL24378816A patent/IL243788B/en active IP Right Grant
- 2016-01-28 CL CL2016000227A patent/CL2016000227A1/en unknown
- 2016-11-21 US US15/357,838 patent/US10071148B2/en active Active
2017
- 2017-06-30 US US15/639,058 patent/US9943579B2/en active Active
2018
- 2018-01-17 AU AU2018200389A patent/AU2018200389B2/en not_active Ceased
2020
- 2020-08-17 AU AU2020220045A patent/AU2020220045B2/en not_active Ceased
- 2020-08-17 AU AU2020220040A patent/AU2020220040B2/en not_active Ceased
- 2020-08-17 AU AU2020220041A patent/AU2020220041B2/en not_active Ceased
- 2020-08-17 AU AU2020220044A patent/AU2020220044B2/en not_active Ceased
- 2020-08-17 AU AU2020220043A patent/AU2020220043B2/en not_active Ceased
- 2020-08-17 AU AU2020220042A patent/AU2020220042B2/en not_active Ceased
- 2020-08-17 AU AU2020220039A patent/AU2020220039B2/en not_active Ceased
- 2020-08-17 AU AU2020220038A patent/AU2020220038B2/en not_active Ceased

Also Published As

Publication number	Publication date
LT3030255T (en)	2020-01-27
TWI777195B (en)	2022-09-11
KR20160038889A (en)	2016-04-07
EA201690016A1 (en)	2016-05-31
TW202041522A (en)	2020-11-16
NZ714163A (en)	2017-07-28
PE20181538A1 (en)	2018-09-26
CN105377290A (en)	2016-03-02
EP3616708A1 (en)	2020-03-04
TW202041516A (en)	2020-11-16
TW202041517A (en)	2020-11-16
EA035362B1 (en)	2020-06-02
ES2764406T3 (en)	2020-06-03
TWI819228B (en)	2023-10-21
KR20200078681A (en)	2020-07-01
CL2016000227A1 (en)	2016-08-05
AU2020220038A1 (en)	2020-09-03
KR20200122417A (en)	2020-10-27
KR20200122418A (en)	2020-10-27
EP3616709B1 (en)	2025-01-15
PE20160717A1 (en)	2016-07-21
AU2020220038B2 (en)	2021-11-25
AU2020220040A1 (en)	2020-09-03
CR20160018A (en)	2016-06-08
CR20180508A (en)	2019-02-27
KR102098327B1 (en)	2020-04-08
SI3030255T1 (en)	2020-02-28
MX389568B (en)	2025-03-20
TWI777196B (en)	2022-09-11
KR20200122419A (en)	2020-10-27
TWI777194B (en)	2022-09-11
TW201900669A (en)	2019-01-01
AU2020220045A1 (en)	2020-09-03
AU2020220044B2 (en)	2021-11-25
KR20200123266A (en)	2020-10-28
JP2016527293A (en)	2016-09-08
EP3616711A1 (en)	2020-03-04
AU2020220041B2 (en)	2021-11-25
AU2014304544A1 (en)	2015-12-03
KR102213554B1 (en)	2021-02-05
DK3030255T3 (en)	2020-01-20
AU2020220045B2 (en)	2021-11-25
AU2020220042A1 (en)	2020-09-03
PT3030255T (en)	2020-01-15
KR102317816B1 (en)	2021-10-26
EP3616711B1 (en)	2025-01-15
CR20210464A (en)	2021-10-26
TW202041515A (en)	2020-11-16
TW202041520A (en)	2020-11-16
PH12015502638A1 (en)	2016-03-07
EP3613427B1 (en)	2025-01-15
EP3616709A1 (en)	2020-03-04
EP3616710B1 (en)	2025-01-15
CR20200139A (en)	2020-09-02
EP3578196A1 (en)	2019-12-11
AU2020220042B2 (en)	2021-11-25
TWI636065B (en)	2018-09-21
EP3456339A3 (en)	2019-03-27
MX2016001426A (en)	2016-05-05
TW201506043A (en)	2015-02-16
BR112016000810A2 (en)	2017-12-12
PE20201284A1 (en)	2020-11-24
RS59861B1 (en)	2020-03-31
AU2018200389B2 (en)	2020-07-16
KR20210008169A (en)	2021-01-20
AU2020220041A1 (en)	2020-09-03
CA3073394A1 (en)	2015-02-12
KR102213552B1 (en)	2021-02-05
KR20180107295A (en)	2018-10-01
US9943579B2 (en)	2018-04-17
US20170319675A1 (en)	2017-11-09
EP3616708B1 (en)	2025-01-08
KR102217680B1 (en)	2021-02-18
AU2020220039A1 (en)	2020-09-03
TW202041518A (en)	2020-11-16
WO2015018805A1 (en)	2015-02-12
TWI777198B (en)	2022-09-11
CN105377290B (en)	2019-09-03
TWI777197B (en)	2022-09-11
CA2912500A1 (en)	2015-02-12
AU2020220044A1 (en)	2020-09-03
AU2020220040B2 (en)	2021-11-25
NZ733168A (en)	2020-04-24
EP3456339A2 (en)	2019-03-20
US20160168200A1 (en)	2016-06-16
AU2014304544B2 (en)	2017-10-26
AU2018200389A1 (en)	2018-02-08
TWI714869B (en)	2021-01-01
AU2020220043A1 (en)	2020-09-03
TW202041521A (en)	2020-11-16
SG10201802399WA (en)	2018-04-27
EP3616710A1 (en)	2020-03-04
AU2020220039B2 (en)	2021-05-20
EP3616712A1 (en)	2020-03-04
SG11201510580UA (en)	2016-02-26
EP3030255A1 (en)	2016-06-15
KR102213556B1 (en)	2021-02-05
TW202041519A (en)	2020-11-16
UA122661C2 (en)	2020-12-28
US20170202937A1 (en)	2017-07-20
AU2020220043B2 (en)	2021-11-25
KR102213551B1 (en)	2021-02-05
CA3020939A1 (en)	2015-02-12
KR102098329B1 (en)	2020-04-09
KR20180105754A (en)	2018-09-28
TWI775117B (en)	2022-08-21
CA3073256A1 (en)	2015-02-12
EP3613427A1 (en)	2020-02-26
EP3616707A1 (en)	2020-03-04
IL243788B (en)	2019-10-31
US10071148B2 (en)	2018-09-11
SG10202002608WA (en)	2020-04-29
HK1222121A1 (en)	2017-06-23
DK3456339T3 (en)	2021-12-06
HUE047079T2 (en)	2020-04-28
CA2912500C (en)	2021-08-24
EP3030255B1 (en)	2019-10-09
IL243788A0 (en)	2016-04-21
EP3456339B1 (en)	2021-10-20
CA3020939C (en)	2023-01-03
PL3030255T3 (en)	2020-05-18
TWI776192B (en)	2022-09-01
KR102211542B1 (en)	2021-02-02

Publication	Publication Date	Title
IL243788A0 (en)	2016-04-21	Novel immunotherapy against several tumors, such as lung cancer, including nsclc
IL295031B1 (en)	2023-04-01	Novel immunotherapy against several tumors, such as lung cancer, including nsclc
GB201507030D0 (en)	2015-06-10	Immunotherapy against lung cancers, in particular NSCLC
EP2971284A4 (en)	2017-01-18	Subtyping lung cancers
EP2968254A4 (en)	2017-03-15	Methods of treating lung cancer
GB201322725D0 (en)	2014-02-05	Cancer therapy
EP3090264A4 (en)	2017-06-07	Circulating tumor cell diagnostics for lung cancer
SG11201509707QA (en)	2015-12-30	Cancer therapy
EP2994148B8 (en)	2017-08-30	Cancer therapy
EP3007756A4 (en)	2017-02-22	Catheter-assisted tumor treatment
EP3044593A4 (en)	2017-05-17	Cancer therapy
EP2961412A4 (en)	2016-11-09	Cancer therapy
EP3015476A4 (en)	2017-05-24	Tumor biomarker
EP3277325A4 (en)	2018-12-05	Combination immunotherapy for small cell lung cancer
GB201313987D0 (en)	2013-09-18	Novel immunotherapy against several tumors, such as lung cancer including NSCLC
IL245477B (en)	2019-12-31	Lung cancer diagnosis
GB201403297D0 (en)	2014-04-09	Novel immunotherapy against several tumors, such as lung cancer, including NSCLC
HK1224926A1 (en)	2017-09-01	Tumor antigens for determining cancer therapy
EP3077812A4 (en)	2017-06-07	Methods for the prognosis of breast cancer
GB201519261D0 (en)	2015-12-16	Novel Immunotherapeutic treatments for tumours
GB201317213D0 (en)	2013-11-13	Cancer Therapy